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 Summary 
Objective: Nonadherence to antiepileptic drugs (AEDs) is a common cause of poor seizure 
control. This study examines whether reported adherence to AEDs is related to variables 
identified in the NICE Medicines Adherence Guidelines as being important to adherence: 
perceptual factors (AED necessity beliefs and concerns), practical factors (limitations in 
capability and resources) and perceptions of involvement in treatment decisions. 
 
Methods:  This was a cross-sectional study of people with epilepsy receiving AEDs. Participants 
completed an online survey hosted by Epilepsy Society (n = 1010), or as an audit during 
inpatient admission (n = 118).  Validated questionnaires, adapted for epilepsy, assessed 
reported adherence to AEDs [Medication Adherence Report Scale (MARS)], perceptions of AEDs 
[Beliefs about Medicines Questionnaire (BMQ)] and patient perceptions of involvement in 
treatment decisions [Treatment Empowerment Scale (TES)].   
 
Results: Low adherence was related to AED beliefs (doubts about necessity: t(577) = 3.90, p < 
0.001) and concerns: t(995) = 3.45, p = 0.001), reported limitations in capability and resources 
(t(589) = 7.78, p < 0.001) and to perceptions of a lack of involvement in treatment decisions 
(t(623) = 4.48, p < 0.001). In multiple logistic regression analyses, these factors significantly (p 
< 0.001) increased variance in reported adherence, above that which could be explained by age 
and clinical variables (seizure frequency, type, epilepsy duration, number of AEDs prescribed).  
 
Significance: Variables identified in the NICE Medicines Adherence Guidelines as potentially 
important factors for adherence were found to be related to adherence to AEDs.  These factors 
are potentially modifiable.  Interventions to support optimal adherence to AEDs should be 
tailored to address doubts about AED necessity and concerns about harm, and to overcome 
practical difficulties, while engaging patients in treatment decisions    
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 Introduction 
 
An estimated 70% of people with epilepsy could have their seizures controlled using anti-
epileptic drugs (AEDs), reducing their risk of serious consequences such as sudden unexplained 
death, seizure and status epilepticus 1; 2.  However, approximately 21-42% of patients 
prescribed AEDs for epilepsy do not adhere to their prescribed treatment3-7.  This nonadherence 
is associated with increases in seizure risk8, risk of hospitalization and treatment costs9; 10 and 
premature mortality 11.  
 
A number of interventions have been designed to support people with epilepsy to self-manage 
their medications and/or adhere to their medication (e.g.12; 13; for review of RCTs see14). 
However, many interventions are not successful, and, even for those that are successful, many 
patients in the intervention group do not achieve high levels of adherence 14. 
 
A comprehensive review, commissioned by the UK National Institute of Health Research (NIHR), 
examined the reasons why interventions to facilitate adherence to medication for long-term 
conditions have met with only limited success15. This drew on theories of medication adherence 
and explanatory studies that had identified potentially modifiable determinants of 
nonadherence across a range of long-term conditions, to recommend a Perceptions and 
Practicalities Approach (PAPA) for supporting adherence16. This approach proposes that 
nonadherence should be seen as a variable behavior rather than a trait characteristic: 
adherence rates vary not just between individuals but within the same person, over time and 
across treatments. Nonadherence may be both intentional and unintentional. In order to 
understand why an individual may or may not adhere to a prescribed treatment we need to 
consider both their motivation and ability. The PAPA suggests that adherence support will be 
more effective if it is tailored to meet the needs of the individual by identifying and addressing 
both the perceptual factors (e.g. beliefs and preferences) and practical factors (e.g. capability 
and resources) that influence the patient’s motivation and ability to start and continue with 
treatment. Within this approach, barriers to adherence combine to cause nonadherence; for 
example, someone who experiences many practical barriers to adherence will need to be more 
motivated to overcome them. The approach also emphasizes the importance of patients’ 
involvement in decisions about their medication. In previous studies, many factors have been 
associated with nonadherence to AEDs.  For example, depression17 18, lack of perceived social 
support19, perceived stigma20 and unemployment21, however no studies have applied the PAPA 
to adherence in epilepsy.  The perceptual factors influencing medication adherence are often 
operationalized as Horne’s Necessity Concerns Framework22. A recent meta-analysis of 93 
 studies published in peer-reviewed journals and covering 23 long-term conditions in 18 
countries, showed that adherence is often related to how individuals judge their personal need 
for treatment and to their concerns about the potential negative effects of taking it. The NICE 
Medicines Adherence Guidelines23 drew on these approaches and also recommended that 
prescribers should involve patients in treatment decisions. 
Based on theories of nonadherence24 , we expected that reported nonadherence to AEDs would 
be associated with more negative beliefs about AEDs (doubts about necessity and concerns), 
more practical barriers (e.g. losing track of time), and to perceptions of involvement in 
treatment decisions. We collected data from two samples of people with epilepsy: an online 
survey collected by a patient charity, and an inpatient sample.  We used the inpatient sample, 
which has an ascertained diagnosis of epilepsy and AED serum levels, to validate the self-
reported adherence questionnaire in the context of online data collection.  
 Methods 
 
The study comprised two cross-sectional samples of people with epilepsy, one recruited 
through an anonymized internet survey supported by a patient charity and the second recruited 
as part of an approved audit at a specialist inpatient referral centre for epilepsy at the National 
Hospital for Neurology and Neurosurgery. Both were exempt from ethics approval 
requirements: the internet survey because it was an anonymized voluntary online survey, and 
the inpatient data because it was an audit, as deemed and registered by the relevant 
independent audit group at the National Hospital for Neurology and Neurosurgery.  
 
Recruitment 
The internet sample was recruited in 2011-12 through Epilepsy Society, an epilepsy charity 
(www.epilepsysociety.org.uk). Participation was entirely voluntary and completely anonymous. 
The online survey link was placed on the website of Epilepsy Society in December 2011. Printed 
copies were available for people without internet access. The survey was promoted via partner 
organizations, radio and social media across the UK.  Other organizations that promoted the 
survey included the International League Against Epilepsy (UK and GP branches), the Epilepsy 
Specialist Nurses Association, and some regional branches of the Neurological Alliance. Posters 
were placed in clinics at the National Hospital for Neurology and Neurosurgery in London. The 
survey was also promoted via Epilepsy Society’s magazine, e-newsletter and social media, and 
via press and radio in Northern Ireland, UK.  
 
In addition, patients admitted to the Sir William Gowers Centre, a multidisciplinary epilepsy 
treatment and assessment centre (a satellite of National Hospital for Neurology and 
Neurosurgery run in partnership with Epilepsy Society) between Jan-Oct 2013 were invited to 
complete the same survey in hardcopy. Patients at the Sir William Gowers Centre have planned 
admissions for assessment: there are no emergency, unplanned admissions.  All patients 
included in this study were therefore already prescribed AEDs and none had treatment 
suspended as a result of an urgent response to another health condition. The needs of the 
patients were considered when distributing the survey. Patients who were admitted for less 
than two days and those with learning disabilities which the clinical team judged would prevent 
them from completing the survey were not given the questionnaire.  Questionnaires were given 
out by staff involved in admissions (receptionist, nurse or support worker) and then returned to 
the reception at any time during the inpatient stay.  Of patients who were admitted for two or 
more days, 43% completed and returned the survey.  No medical staff were involved in the 
process and patients were informed that their responses would have no effect on their care.   
  
Participants 
In total, 1595 people with epilepsy participated through the internet survey (48 completed on 
paper) and 119 people with epilepsy completed the survey from the inpatient facility. We 
excluded 531 incomplete responses, and 55 complete responses from the internet survey: 33 
who stated they lived outside the UK; 6 who completed the survey on behalf of someone else; 
and 16 who were not currently taking epilepsy medication. All remaining patients were UK 
resident, completed the questionnaire on behalf of themselves and were currently prescribed 
AEDs. One inpatient was readmitted and participated a second time; their second response was 
subsequently excluded. The final sample comprised 1127 people, of whom 118 were inpatients. 
 
Questionnaire measures 
The following measures were included in the survey. 
 
Demographic and clinical variables 
Participants were asked to report their age, how long they had had epilepsy, how often they had 
seizures, and what type or types of seizures they have:    
seizures where I… 
 ‘am aware of what is happening (such as simple focal seizures)’ 
‘am confused or only partly aware (such as complex focal seizures)’ 
‘briefly lose consciousness (such as absences, tonic and atonic seizures)’ 
‘lose consciousness and jerk or convulse (such as tonic clonic seizures)’ 
Participants were also asked to indicate which medications they were currently taking from a 
list of 24 AEDs. 
 
BMQ-Epilepsy Specific Scales 
The BMQ-Epilepsy Specific scale25 (©R Horne) was an adapted version of the BMQ-Specific 
scale26 designed to assess respondents’ belief in their personal need for their AED (AED 
Necessity) e.g. ‘I would prefer to take my epilepsy medicine rather than risk having a seizure’, 
and their concerns about the potential adverse consequences of their AED (AED-Concerns) e.g. 
‘I sometimes worry that my epilepsy medicine slows me down’. The AED-Necessity scale has six 
items and the AED Concerns scale has ten items. Post-hoc Cronbach’s α indicated that both had 
adequate internal reliability (AED-Necessity α=0.79; AED-Concerns α=0.80). All items were 
rated on a 5-point Likert-type scale (Strongly Disagree=1, Agree=2, Uncertain=3, Disagree=4 
and Strongly Disagree=5). Scores were pro-rated and then mean item scores (range 1-5) were 
 computed by dividing the scale score by the number of items in the scale. Higher scores indicate 
higher agreement with the construct represented by the scale. 
 
A Necessity-Concerns Differential (NCD) was calculated by subtracting AED-Concerns scores 
from AED-Necessity scores. The NCD score provides a numerical indicator of how the individual 
judges their personal need for AED relative to their concerns about the potential negative 
effects of taking AEDs. NCD scores range from -4 to +4, with positive scores indicating higher 
ratings of AED-Necessity relative to AED-Concerns. 
 
Finally, we divided patients into four attitudinal groups by dichotomizing participants at the 
scale midpoints: AED-Necessity (less than 3 as Low AED-Necessity) and AED-Concerns (greater 
than 3 as High AED-Concerns). Participants were then grouped into patients who were 
Accepting (High Necessity, Low Concerns), Indifferent (Low Necessity, Low Concerns), Sceptical 
(Low Necessity, High Concerns) or Ambivalent (High Necessity, High Concerns) about AED 
treatment27; 28.  
 
An additional new BMQ 6-item subscale, the AED Practical Barriers Scale (©R Horne), assessing 
practical barriers to adherence to AEDs, was also included.  Participants were asked to rate the 
frequency with which they experienced six barriers to adherence e.g. ‘I have difficulty 
swallowing my medication’, on a 5-point Likert-type scale, from 1=Always, 2=Often, 
3=Sometimes, 4=Rarely, and 5=Never. The scale had adequate reliability, Cronbach’s α = 0.74, 
but has not been previously validated.  
 
Treatment Empowerment Scale 
The Treatment Empowerment Scale (TES) is a validated measure of patients’ perceptions of 
empowerment during medical consultations, and their perceived degree of involvement in 
decisions about treatment29, e.g. ‘The decision to start or stop medication is mine, not the 
doctor’s’.  Respondents were asked to rate their agreement with ten statements regarding their 
communication with their doctor about their epilepsy medication on a 5-point Likert scale 
(1=Strongly Agree, 2=Agree, 3=Unsure, 4=Disagree, 5=Strongly Disagree). These response 
options were adapted from the original choices to make them consistent with the other scale 
formats used within this study.  As with the original scale, scores were reversed where 
appropriate, pro-rated and summed to form a total score (range 10-50). The scale had adequate 
reliability, Cronbach’s α = 0.82.   
  
Medication Adherence Rating Scale  
 A 10-item version of the Medication Adherence Rating Scale (MARS30) was used to assess 
patients’ adherence to their medication. This version of the MARS was adapted for epilepsy. 
Although the MARS has been previous validated30 e.g. against prescription refill databases31 32, 
electronic adherence monitors33 and serum concentration of medication34, our adaptation of the 
scale has not been validated.  Patients rated ten medication-taking behaviours (e.g. ‘I decide to 
miss out a dose’) on a 5-point Likert-type scale (1=Always, 2=Often, 3=Sometimes, 4=Rarely, 
and 5=Never). A total adherence score, with higher scores indicating higher adherence, range 
10-50, was calculated by summing responses on this scale. The scale had good internal 
reliability (Cronbach’s α = 0.83). As with previous studies, scores were pro-rated and then the 
total scale scores were dichotomized, with the third of patients scoring the lowest on self-
reported adherence (≤ 44) grouped into ‘low adherence’ and the highest two-thirds (≥45) 
grouped into ‘high adherence’25; 28.  We described the groups as high and low rather than 
adherent and non-adherent as we recognized that some of the participants in the high adherent 
group did not report full adherence and may even have responded ‘always’ to one of the items. 
 
AED blood level assessment 
The inpatient sample had AED serum levels measured at the hospital’s accredited Therapeutic 
Drug Monitoring laboratory using quality-controlled standardized procedures as part of routine 
clinical care.  Where participants had recorded AED levels on admission or the first full day as 
an inpatient we assumed that AED levels would be indicative of their adherence behavior 
outside the hospital. Levels of AEDs were categorized as within established reference ranges 
(http://www.epilepsysociety.org.uk/using-tdm-service#.VEwJCRaEywQ), under or above the 
reference range for a given AED, or undetectable.  AED serum levels have been validated as an 
adherence assessment in several previous studies35-37. 
 
Analysis  
Data were analyzed using IBM SPSS Statistics 21. Independent samples t-tests were used to test 
for differences between high and low adherence group on perceptions of AED (AED Necessity 
and AED Concerns), AED Practical Barriers (e.g. difficulty swallowing or losing track of time) 
and perceptions of involvement in treatment decisions.  Standardized effect sizes (Cohen’s d) 
were calculated to allow the size of these differences to be compared.  Correlations were used to 
assess relationships between perceptions of AED (AED Necessity and AED Concerns), AED 
Practical Barriers (e.g. difficulty swallowing or losing track of time) and perceptions of 
involvement in treatment decisions. Logistic regression was used to assess the relationship 
between clinical, demographic, perceptual and practical factors and adherence. Predictors were 
entered into multivariable analysis dependent on our hypotheses rather than based on which 
 variables were significant predictors of adherence in univariable analyses. Nagelkerke’s R2 was 
used as an estimate of the proportion of variance in nonadherence accounted for by each 
predictor. Nagelkerke’s R2 is a pseudo R2 statistic which is not equivalent to R2 in OLS regression 
but which enables comparison of how well different logistic regression models fit a particular 
data set.  Hierarchical stepwise logistic regression was used to assess the combined value of 
perceptual and practical barriers and treatment empowerment (added at the final step) in 
predicting adherence after controlling for demographic (age) and clinical variables (seizure 
frequency, type, epilepsy duration, number of AEDs prescribed).  
 
 
Results  
 
The results in both samples were very similar and therefore the online and inpatient samples 
are combined within these results.  Detailed data, including individual item responses for both 
samples separately, are included within the supplementary information. 
 
Clinical and Demographic Variables  
Approximately three quarters of the respondents (71.4%, n = 804) were aged 25-59.  Around 
one third of respondents (n = 396, 35.3%) reported they had been diagnosed with epilepsy for 
more than 20 years. Just over two-thirds of respondents reported that they had had at least one 
seizure in the previous year (n = 743, 68.2%). Participants could report that they experienced 
multiple seizure types. The most frequent type of seizure reported were those where patients 
lost consciousness and jerked or convulsed (e.g. tonic-clonic seizures), reported by 683 
participants (60.6%). See Table 1 for full descriptive statistics. 
 
A single medication was taken by 43.9% of participants (n = 495); two medications were taken 
by 31.1% (n = 351), with the remainder of participants taking more medications.  The most 
common AED was levetiracetam, taken by 36.4% (n = 410) of participants, followed by 
lamotrigine taken by 32.7% (n = 369), and carbamazepine, 26.2% (n = 295). The proportions of 
respondents taking each particular AED are shown in Figure 1 (in the Supplementary 
information).  
 
Adherence to AEDs 
MARS scores were dichotomized using the scale midpoint (see Table 2) to form two groups, a 
group reporting high adherence (n = 764, 68.3%) and a group reporting low adherence (n = 
355, 31.7%).    
  
Sixty-three patients (52.9%) of the inpatient sample had AED blood levels taken on admission 
or during their first full day as an inpatient. Eight patients’ blood levels indicated that at least 
one prescribed AED was undetectable, suggesting nonadherence.  MARS scores were 
significantly lower for those patients who had any AED undetectable blood level than for other 
patients (Mann-Whitney U = 328.5, p = 0.02). Of patients who had an undetectable blood level, 
50.0% (n = 4) were also categorized as low adherent on the MARS. Conversely, of the 55 
patients whose drug levels indicated the presence of at least one AED, 83.6% (n = 46) were also 
categorized as highly adherent on the MARS.  This suggests the self-report data was associated 
with blood level indicators of taking AEDs. 
 
Attitudinal Analysis of Perceptions of AEDs 
Participants were categorized into attitudinal groups based on whether they scored above or 
below the scale midpoint for the AED Necessity and AED Concerns scales (see Figure 1) into 
high/low concerns and high/low necessity groups.  These dichotomized scores were then used 
to split patients into attitudinal groups. Approximately half of all participants (n = 595; 52.8%) 
were ‘Ambivalent’ about their AEDs, having a strong belief that they needed their AEDs but also 
high concerns about their medicines. Just over a third of participants were ‘Accepting’ of their 
AEDs (35.7%, n = 402), having low concerns and high necessity beliefs. Small proportions of 
patients were ‘Skeptical’, having both high doubts about their personal need for AEDs and high 
concerns (5.9%, n = 67) or ‘Indifferent’, reporting low concerns and low beliefs in their need for 
AEDs (4.9%, n = 55). 
 
 
Practical Barriers to Taking AEDs 
Factor analysis identified a single factor underlying the AED Practical Barriers scale. The median 
total score for the scale was 9.0 (IQR: 7.00-13.00) indicating that the majority of participants 
said that they never or rarely experienced most of the practical barriers. To aid interpretation, 
we counted the number of practical barriers which patients reported experiencing rarely, 
sometimes, often or always. The median number of practical barriers reported was 2 (IQR: 1-4). 
Approximately a fifth of participants (20.8%, n = 226) reported that they experienced none of 
the practical barriers to taking their AEDs. 
 
Perceptions of Involvement in Treatment Decisions 
 Participants’ scores on the treatment empowerment scale (TES; mean = 3.35, s.d.= 0.74) were 
around the response midpoint of 3 or Uncertain, indicating that many participants did not feel 
highly involved in treatment discussions and decisions. 
 
Relationships Between Adherence to AEDs, Perceptual and Practical Barriers to Adherence and 
Perceptions of Involvement in Treatment Decisions 
Participants in the Low Adherence group rated their personal need for AEDs lower, and their 
concerns about AEDs higher, than the High Adherence group. Consistent with this, their overall 
judgment of AEDs was more negative, as indicated by lower AED NCD scores. Participants who 
reported low adherence also had higher scores on the practical barriers scale (see Table 3).  
Comparison of the standardized effect sizes, d, indicated that the largest difference between the 
high and low adherence groups was on the practical barriers scale. 
 
Participants in the low adherence group viewed themselves as less involved in treatment 
decisions than participants in the high adherence group (see Table 3).  Patients who rated 
themselves as more involved in treatment decisions (TES) reported fewer practical barriers, 
r(1112) = -0.12, p < 0.001.  They also had fewer concerns about possible adverse effects of AEDs 
(AED Concerns), r(1114) = -0.26, p <0.001, a stronger belief in their personal need for AEDs 
(AED Necessity) r(1112) = 0.17, p < 0.001, and were more positive about AEDs overall (AED 
NCD), r(1092) = 0.15, p < 0.001.  
 
Can PAPA Variables Add to the Variance in Adherence to AEDs Explained by  Demographic and 
Clinical Variables? 
Hierarchical multiple logistic regression analysis (see Table 4) was conducted to test whether 
perceptual (AED Necessity and Concerns) and practical barriers (AED Practical Barriers) and 
perceptions of involvement in treatment decisions (TES) predicted adherence when controlling 
for clinical and demographic variables. When age, duration of epilepsy, seizure type, seizure 
frequency and number of different AEDs prescribed were forced into the model at Step 1, only a 
small proportion of the variance in adherence was predicted (See Table 4). Age of patients and 
the duration of their epilepsy were associated with adherence. The 60-84 year old age group 
reported the highest level of adherence. In addition, epilepsy duration also predicted a 
significant amount of the variance in adherence, with participants who reported that they had 
epilepsy for 4-10 years being at significantly higher risk of nonadherence than patients who 
reported that they had epilepsy for more than 20 years. Patients who were prescribed multiple 
AEDs reported higher adherence than patients who were on one AED. The Nagelkerke’s R2 of 
 0.07 for this step illustrated that although the model was significant, χ2(15, N = 1144) = 52.64, p 
< 0.001, the relationship between the predictors and adherence was not strong.  
 
When we entered perceptual and practical barriers and involvement in treatment decision 
variables in Step 2 (AED Necessity, AED Concerns, AED Practical Barriers, TES), Nagelkerke’s R2 
increased to 0.18 indicating a stronger relationship. Low adherence was associated with 
reduced necessity beliefs (AED Necessity) and increased reported practical barriers to 
medication taking (AED Practical Barriers). The relationship between AED Concerns and 
adherence was not significant in the multivariable model. Participants who reported more 
involvement in discussions about treatment were less likely to report low adherence.  
 
 
  
 Discussion 
We found that nonadherence to AEDs was best understood in terms of how each individual 
interacted with their treatment.  Patients’ perceptions of their AEDs (necessity beliefs and 
concerns), their involvement in treatment decisions and their ability to deal with the ‘practical’ 
issues of taking daily medication as advised, were much more strongly related to nonadherence 
than clinical and demographic variables (including age, number of medications taken, seizure 
type and epilepsy duration).  
 
Our findings are consistent with previous studies linking nonadherence to AEDs to patients’ 
beliefs about AEDs (doubts about personal need for daily AEDs and concerns about potential 
adverse effects)25; 38-41.  But they go further by assessing the value of other factors specified as 
potentially important in the NICE Medicines Adherence Guidelines23. This is the first study to 
measure the three variables that NICE considered most important for adherence (patients’ 
beliefs and concerns, satisfaction with involvement in the treatment decision and ‘practical’ 
support with using medication) and quantify their relationship to AED adherence.  In the 
univariable analyses, all these factors were significantly associated with adherence, and in the 
multivariable analysis practical barriers, doubts about necessity and satisfaction with 
involvement in treatment decisions all remained significant predictors, suggesting that all of 
these factors would need to be addressed in adherence interventions.  Although the size of 
relationships between reported adherence and barriers to medication-taking were in the range 
of small-medium effects, we believe that these factors are still important for healthcare 
professionals to consider when supporting people with epilepsy.  Reassuring patients regarding 
their medication and explaining why treatment with AEDs is needed may be a relatively quick, 
low risk and low-cost way of improving outcomes for patients.  Concerns about medication have 
also been linked to reduced quality of life, and increased reporting of side effects. Addressing 
these barriers to adherence may therefore be of a wider benefit to patients.    
 
As suggested within the NICE Medicines Adherence Guidelines23, these relationships provide 
useful information for the development of adherence support interventions for epilepsy; by 
addressing doubts about need for AEDs, concerns about adverse effects and practical barriers to 
medication-taking, healthcare providers may be able to support people with epilepsy to adhere 
to AED treatments.  Previous research (for systematic review see14) has suggested that intensive 
reminders and interactive interventions may be the most effective at improving adherence. Our 
results suggest this support might be more effective if it is tailored to address both perceptions 
and practicalities. To do this we need to look beyond the provision of ‘practical support’ 
designed to improve the patient’s ability to adhere (e.g. reminders, clear instructions, simple 
 regimens etc.), to consider the perceptual factors (e.g. beliefs about AEDs and involvement in 
treatment decisions) that influence the motivation to keep taking the treatment. 
 
Reports of increased involvement in decisions about AED treatment were associated with 
higher adherence. This is reassuring, as it has been suggested that patients who feel that they 
have more choice over treatments may choose not to adhere42. Potentially, patients who are 
more involved in treatment decisions have more opportunity to express concerns and doubts 
about treatment to their physicians, and for these concerns and doubts to be addressed, with 
subsequent positive impact on adherence.  
 
Beyond the effects on adherence, our findings suggested that many participants adhered to 
treatment despite concerns and doubts about their AED treatment.  This was true even of our 
high adherence group who had an adherence score of greater than 44 (equivalent to saying that 
they ‘sometimes’ did 3 of the 10 nonadherent behaviours).  More than half of the sample 
reported ambivalence about taking AEDs, expressing both high belief in their personal need for 
AEDs and high concerns about the potential negative effects of AEDs.  Approximately 80% of 
participants reported at least one practical barrier to taking their AEDs.  It is likely that these 
concerns and doubts, even if not affecting adherence, may affect other aspects of participants’ 
response to their epilepsy.  For example, patients’ emotional response to treatment or 
relationship with their physician may be affected by unaddressed ongoing concerns.  
   
There are several caveats to our findings.  They are largely dependent on self-reported 
information; respondents may have misreported their diagnosis or adherence levels. The 
findings from the online sample are similar to those from the inpatient sample however, 
offering some reassurance from an inpatient sample who had a diagnosis of epilepsy confirmed 
by a specialist neurology team. To validate self-reported adherence, we attempted to compare 
AED blood levels with self-reported adherence (MARS scores) where these were available and 
found some evidence that these were associated.  However, both assessments are limited.  Self-
report adherence measures have been validated against more objective measures of adherence, 
but patients may over-report adherence34. Likewise, AED blood level data may give a falsely 
pessimistic view of patients’ adherence when AED half-life is short, or optimistic, in the case of 
‘white coat’ adherence where patients increase medication intake immediately before a blood 
test.  Even where accurate, MARS scores or AED levels may not correspond to clinical outcomes.  
Adherence is complex e.g. taking a certain combination of doses at particular times 
with/without certain foods, for a defined number of days.  Particular types of nonadherence 
may drive clinical outcomes for epilepsy patients (e.g. missing 2 doses on consecutive days may 
 have a greater effect than missing 1 dose/week for 2 weeks), and these could vary between 
patients or drugs (e.g. due to different absorption rates).  We also cannot be certain that either 
the inpatient or online samples are representative of other epilepsy patients in general; we may 
have oversampled adherent patients who are more engaged with their care, or conversely 
patients who viewed it as an opportunity to express dissatisfaction with their treatment.  
 
This survey was also cross-sectional and therefore we can show association but not prove that 
the PAPA variables or age/epilepsy duration caused nonadherence to AEDs. Some potentially 
unexpected relationships emerged; higher adherence in people who reported taking multiple 
AEDs than monotherapy,  lower adherence in those with a more recent onset of epilepsy, a lack 
of association between seizure type and frequency and adherence.  But, because the study is 
cross-sectional, we cannot draw firm conclusions regarding the causal relationships.  For 
example, the link between epilepsy duration and adherence could indicate patients become 
more adherent to their medication over time, perhaps as they become more familiar and 
reconciled to their medication or develop habitual medication-taking routines. However, 
confounding factors, such as changes in prescribing patterns, may also contribute to this pattern 
of results. Likewise, people who have recent seizures or multiple medications may be receiving 
more healthcare support or perceive a greater need for treatment, and therefore have increased 
adherence. Longitudinal studies, tracing these variables over time, would be a more robust test 
of these relationships. These findings are reliant on participants accurately reporting their 
adherence, involvement in treatment decisions, and perceptual and practical barriers to 
adherence.  We deliberately asked for very minimal information on demographic and other 
factors.  For example, we did not collect data on educational level or ethnicity.  It was felt that 
the questionnaire would be more acceptable to participants if we did not ask for this personal 
information. We acknowledge that this means that we cannot draw any conclusions about the 
generalizability of these findings across patients from different sociodemographic groups.  
Finally, given this and the sampling method (single site plus online) we cannot be sure whether 
the respondents were representative of people with epilepsy across the UK or beyond. It is 
likely that the sample may have contained, for example, patients who had more time to 
complete the survey, were more motivated to participate, or had better internet access than 
people who did not participate.  
 
This study builds on previous evidence demonstrating the importance of concerns about AEDs 
and doubts about treatment need in explaining nonadherence in epilepsy and demonstrates 
that perceptual barriers and a lack of involvement in decisions about treatment are also barriers 
to adherence. Interventions to address doubts about perceived need for AEDs, concerns about 
 adverse effects, and practical factors influencing medication taking may help epilepsy patients 
to better adhere to AEDs. There is a need to develop such interventions and test whether they 
are feasible, acceptable and effective methods of supporting people with epilepsy to adhere to 
their AEDs.  
 
Key Points 
 
 Low adherence was related to perceptual barriers: doubts about AED necessity, 
concerns about the potential adverse effects of treatment 
 Low adherence was associated with perceptions of practical barriers to medication 
taking and lack of involvement in treatment decisions 
 These factors had small to moderate effects on adherence, whereas reported clinical and 
demographic factors had very small effects 
 Addressing concerns and doubts about AEDs, reducing practical barriers and engaging 
patients in treatment decisions may support adherence 
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 Tables 
 
 n (%)  
Agea   
Under 16 years 46 (4.1%)  
16-24 years 174 (15.4%)   
25-40 years  420 (37.3%)  
41-59 years 384 (34.1%)  
60-84 years 102 (9.1%)  
Epilepsy durationb   
3 or fewer years 194 (17.3%)  
4-10 years 254 (22.7%)  
11-20 years 277 (24.7%)  
more than 20 years 396 35.3%  
Seizure frequencyc   
about daily 155 (14.2%)  
about weekly 221 (20.3%)  
about monthly 360 (33.1%)  
seizure free for more than a year 346 (31.8%)  
Seizure type (seizures where I…)   
… am aware of what is happening  354 (31.4%)  
… am confused or only partially aware  449 (39.8%)  
… briefly lose consciousness  448 (39.8%)  
…lose consciousness and jerk or convulse  683 (60.6%)  
 
Table 1: Age, epilepsy duration and seizure characteristics. 
Note. a 1 online participant missing from this analysis; b 3 online participants and 3 clinic 
participants missing from this analysis; c 38 participants missing from this analysis 
  
  
 
 
 
 
 
 
 
 
 
 
Table 2: PAPA variables in 
high and low adherence groups. 
Note: a 5 participants missing; b 3 participant missing. 
AED = antiepileptic drugs; NCD = Necessity-Concerns Differential; TES = Treatment Empowerment Scale 
  
 High adherence 
n = 765 
m (sd) 
Low adherence 
n = 355 
m (sd) 
 
 
d [95% CI] 
 
     
AED Necessity a 3.94 (0.73) 3.73 (0.89) 0.27 [0.14,0.39] t(577) = 3.90, p < .001 
AED Concerns b 3.16 (1.12) 3.35 (0.73) -0.19 [-0.31,-0.06] t(995) = 3.45, p = .001 
AED NCD a 0.78 (1.25) 0.38 (1.19) 0.32 [0.20,0.45] t(1112) = 5.13, p < .001 
AED Practical Barriers 
b 
11.70 (4.39) 9.61 (3.64) 0.58 [0.45, 0.70] t(589) = 7.78, p < .001 
TES  3.41 (0.70) 3.20 (0.79) 0.29 [0.16, 0.41] t(623) = 4.48, p < .001 
  
Predictor B OR RN2 
STEP 1: Demographic and Clinical 
Variables 
  .064*** 
Age    
Under 16 years -0.57 0.56 [0.19, 1.67]  
16-24 years -1.30 0.27** [0.13, 0.59]  
25-40 years -1.18 0.31** [0.15, 0.63]  
41-59 years -0.84 0.43* [0.21, 0.88]  
60-84 years REF   
Epilepsy duration    
3 or fewer years 0.83 2.30** [1.37, 3.86]  
4-10 years -0.15 0.86 [0.57, 1.30]  
 11-20 years 0.19 1.21 [0.80, 1.81]  
more than 20 years REF   
Seizure frequency    
about daily 0.12 1.12 [0.67, 1.88]  
about weekly -0.42 0.66 [0.43, 1.01]  
about monthly -0.20 0.82 [0.56, 1.19]  
seizure free for about 1 year REF   
Seizure type (seizures where I…)    
… am aware of what is happening  -0.33 0.74 [0.54, 1.01]  
… am confused or only partially aware  0.04 1.04 [0.76, 1.43]  
… briefly lose consciousness  -0.05 0.95 [0.70, 1.29]  
…lose consciousness and jerk or convulse  -0.18 0.84 [0.62, 1.14]  
Medication regimen    
2 or more AEDs taken vs <2 0.38 1.46* [1.06, 2.00]  
    
STEP 2: PAPA variables   0.178*** 
AED Necessity 0.46 1.58*** [1.30, 1.92]  
AED Concerns -0.22 0.80 [0.66, 1.45]  
Practical Barriers  -0.13 0.87*** [0.84, 0.91]  
TES  0.23 1.26*[1.02, 1.55]  
Table 3: Multiple logistic regression predicting adherence using the PAPA controlling for 
clinical and demographic variables at Step 1.  Note.* p < .05, ** p < 0.01, *** p < 0.001; 
AEDs = antiepileptic drugs; TES = Treatment Empowerment Scale.   
 Figure captions 
Figure 1: Attitudinal analysis of perceptions of AEDs. 
 
Supplementary information Figure Captions 
 
Figure S1: Proportion of respondents taking each AED. AEDs which fewer than 5% of patients 
were taking are omitted (pregabalin, phenobarbital, acetazolamide, gabapentin, primidone, 
eslicarbazepine, rufinamide, ethosuximide, vigabatrin, piracetam, stiripentol, tiagabine). 
 
Figure S2: Percentages of respondents expressing doubts about their need for AEDs, as 
indicated by responding ‘uncertain’, ‘disagree’ or ‘strongly disagree’ on AED Necessity items. 
 
Figure S3: Percentages of respondents expressing concerns about AEDs, as indicated by 
responding ‘agree’ or ‘strongly agree’ on AED Concerns items. 
 
Figure S4: Percentages of respondents reporting experiences of practical barriers to taking 
AEDs, as indicated by responding ‘rarely’, ‘sometimes’, ‘often’ or ‘always’ on Practical 
Barriers items. 
 
Figure S5: Percentages of respondents reporting experiences of involvement in decisions 
about treatment, as indicated by responding ‘agree’ or ‘strongly agree’ on Treatment 
Empowerment Scale items.  
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